



Therachon Appoints Dr. Maarten Kraan, Ph.D., M.D., Chief Medical Officer

Basel, Switzerland – March 21, 2017 – Therachon AG, a biotechnology company focused on rare genetic diseases, announced today it has appointed Dr. Maarten Kraan, Ph.D., M.D., to the role of Chief Medical Officer.

“We are delighted to welcome Dr. Kraan as Therachon’s Chief Medical Officer,” said Luca Santarelli, M.D., Therachon’s Chief Executive Officer and Director. “Dr. Kraan’s wealth of translational and drug development expertise is critical during this exciting time in our company’s growth. He will play a key role in guiding TA-46 from discovery into clinical development and helping us fulfill our mission of developing medicines for rare, genetic diseases.”

Most recently, Dr. Kraan was Senior Vice President, Head of Innovative Medicines Respiratory and Inflammation at AstraZeneca. Prior to that, Dr. Kraan was Vice President, Head of Clinical Research and Experimental Development Inflammation at Hoffman – La Roche. Before that, Dr. Kraan was Vice President, Immunosciences at Bristol Myers Squibb. Dr. Kraan began his pharmaceutical career at Schering Plough, holding roles of increasing responsibility, including Senior Global Medical Director Immunology, Global Medical Affairs. Dr. Kraan is currently serves as an Adjunct Professor at Goteborg University (Sweden). Dr. Kraan held numerous academic, editorial and hospital positions before entering the pharmaceutical industry. He received his Ph.D. in immunology and M.D. from Leiden University (Netherlands).

About Therachon

Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. This rare genetic condition affects about one in 25,000 children and is caused by a genetic mutation of the FGFR3 receptor, which stunts child bone growth. Therachon is committed to translating the promise of its science into new treatments for patients with high unmet medical needs. For more information, visit www.therachon.com.

Visit us on [Twitter](#). Visit us on [LinkedIn](#)..

###

Media Contact

Katie Engleman
Pure Communications, Inc.
(919) 333-7722
KENGLEMAN@PURECOMMUNICATIONSINC.COM